Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Low-grade Central Osteosarcoma of the Metatarsal Bone: A Clinicopathological, Immunohistochemical, Cytogenetic and Molecular Cytogenetic Analysis

JUN NISHIO, HIROSHI IWASAKI, SATOSHI TAKAGI, HAJIME SEO, MIKIKO AOKI, KAZUKI NABESHIMA and MASATOSHI NAITO
Anticancer Research December 2012, 32 (12) 5429-5435;
JUN NISHIO
1Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jnishio{at}cis.fukuoka-u.ac.jp
HIROSHI IWASAKI
2Department of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SATOSHI TAKAGI
3Department of Plastic and Reconstructive Surgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HAJIME SEO
1Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MIKIKO AOKI
2Department of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUKI NABESHIMA
2Department of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASATOSHI NAITO
1Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Low-grade central osteosarcoma (LGCOS) is a very rare low-grade malignant neoplasm that is often confused with a variety of benign fibro-osseous lesions. It rarely involves the small tubular bones of the feet. We present an unusual case of LGCOS arising in the third metatarsal bone of a 16-year-old boy. The radiographic appearance was suggestive of a benign lesion. An open biopsy was performed and the initial diagnosis was fibrous dysplasia. The patient underwent curettage of the lesion and packing of the bony defect with a synthetic bone substitute. Histologically, the curetted specimens consisted of spindle cells admixed with irregular bony trabeculae and osteoid. The spindle cells were fairly uniform with mild atypia, and cellularity varied from low to high. Immunohistochemistry showed that the tumor cells were focally-positive for cyclin-dependent kinase 4 and p53, but negative for murine double minute-2. The MIB-1 labeling index was 36.7% in the highest focus. Cytogenetic analysis exhibited the following clonal karyotypic abnormalities: 48,XY,del(6)(p11),add(8)(q24),add(12)(p11.2),+mar1,+mar-2. Spectral karyotyping demonstrated that marker chromosomes were composed mainly of chromosome 6. Metaphase-based comparative genomic hybridization analysis showed a high-level amplification of 6p12-p21 and gains of 8q21-q24, 10p15, 12q13-q15, and 16q23-q24. Based on these findings, the final diagnosis was revised to LGCOS and the patient was treated with an additional wide excision, followed by reconstruction with a free-vascularized osteocutaneous scapular flap. At 18 months of follow-up, the patient is well with no evidence of local recurrence or distant metastasis. Our case highlights the diagnostic difficulty of this tumor with limited tissue samples and the importance of immunohistochemical and molecular cytogenetic analyses in ambiguous cases.

  • CDK4
  • cytogenetics
  • low-grade central osteosarcoma
  • MDM2
  • metatarsal bone

Low-grade central osteosarcoma (LGCOS) is a rare but distinct variant of osteosarcoma, accounting for only 1-2% of all osteosarcomas (1). It tends to occur in the metaphysis of long bones, particularly the distal femur and the proximal tibia, and has a peak incidence in the second and third decades of life with no gender predilection. Patients present with intermittent pain, with or without swelling, usually of long duration. The treatment of choice for LGCOS is wide excision, and there is no role for chemotherapy. Unlike conventional osteosarcoma, LGCOS has a relatively good prognosis when treated appropriately.

Histologically, LGCOS consists of spindle cells arranged in an interlacing pattern. These cells exhibit subtle cytological atypia, and rarely carry mitotic figures. The matrix is produced as well-formed bony trabeculae. In some cases, the bone has a classic ‘Chinese character’ appearance of fibrous dysplasia. De-differentiation may be found either at the time of initial presentation (2-4) or at recurrence (5) and is associated with a poor prognosis (5). Immunohistochemically, the tumor cells are frequently positive for murine double minute-2 (MDM2) and/or cyclin-dependent kinase-4 (CDK4) (6, 7).

There have been very few cytogenetic studies of LGCOS (8, 9), and no recurrent chromosomal abnormalities have been detected. Metaphase and array-based comparative genomic hybridization (CGH) analyses have demonstrated gain or amplification of 12q13-q15 containing MDM2 and CDK4 (7, 10). Amplification of tetraspanin-31 (formerly known as SAS), located on chromosome 12q13, has also been identified in 15% of LGCOS by quantitative polymerase chain reaction (11).

Only a very small number of LGCOS involving the metatarsal bone have been reported in the literature (12-14). Herein we report an unusual example of LGCOS arising in the third metatarsal bone of an adolescent male with chromosome 6p alterations. We also review the cytogenetic and molecular cytogenetic characteristics of LGCOS, as well as its clinicopathological and immunohistochemical features.

Case Report

A previously good in general health, 16-year-old boy presented with an 18-month history of intermittent pain and swelling in the dorsum of the left foot. There was no history of antecedent trauma. Radiographs demonstrated an expansive lytic lesion in the third metatarsal bone without evidence of cortical destruction or periosteal new bone formation (Figure 1). No cortical destruction or soft tissue extension was seen on computed tomography nor on magnetic resonance imaging. The lesion exhibited intermediate signal intensity on T1-weighted sequences (Figure 2A) and moderately high signal intensity on T2-weighted sequences (Figure 2B). T1-weighted contrast-enhanced fat-suppressed sequences showed marked enhancement of the lesion (Figure 2C). A bone scintigraphy showed markedly increased uptake in the third metatarsal bone corresponding to the lytic lesion. Based on the clinical and radiological features, a benign condition, such as giant-cell reparative granuloma, was strongly suggested.

The patient underwent an open biopsy, and the initial pathological diagnosis was fibrous dysplasia (Figure 3). Intralesional curettage and packing of the bony defect with a synthetic bone substitute were performed. Grossly, the tumor was well-demarcated, firm, and grayish-white. Microscopically, the tumor consisted of spindle cells admixed with irregular bony trabeculae and osteoid (Figure 4A). Hypercellularity, mild cellular atypia, and scattered mitotic figures were observed (Figure 4B). Immunohistochemically, the tumor cells were focally positive for CDK4 (Figure 4C) and p53, but negative for MDM2. The MIB-1 labeling index was 36.7% in the highest focus (Figure 4D). The pathological diagnosis of the curetted specimens was revised to LGCOS.

Cytogenetic analysis revealed a complex karyotype-including marker chromosomes (Figure 5). The karyotype was as follows: 48,XY,del(6)(p11),add(8)(q24), add(12)(p11.2), +mar1,+mar2[3]/48,idem,add(15)(q24),add (20)(p11.2)[2]/46,XY[15]. Spectral karyotyping (SKY) analysis showed that marker chromosomes were mainly composed of chromosome 6 (Figure 6). Metaphase-based CGH analysis showed a high-level amplification of 6p12-p21 and gains of 8q21-q24, 10p15, 12q13-q15, and 16q23-q24 (Figure 7). No significant loss of DNA sequences was found.

Two months after curettage, the patient underwent an additional wide excision, followed by reconstruction with a free vascularized osteocutaneous scapular flap. No chemotherapy was administered. At 18 months of follow-up, the patient is well with no evidence of local recurrence or distant metastasis.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Plain radiographs of the left foot showing an expansive lytic lesion in the third metatarsal bone, without evidence of cortical destruction.

Discussion

LGCOS of the metatarsal bone is extremely rare; only four cases have been to date reported in literature (12-14). As in our case, a preoperative diagnosis of benign conditions, such as enchondroma and fibrous dysplasia, was made in two of those cases (12, 14). Moreover, even LGCOS involving the long bones was initially diagnosed as a benign condition in 40% of cases (15). These findings suggest that it may be difficult or impossible to clinico-radiologically distinguish LGCOS from benign fibro-osseous lesions without the presence of some degree of cortical destruction and/or soft tissue extension.

The differential diagnosis of LGCOS includes fibrous dysplasia and desmoplastic fibroma. The absence of cytological atypia and the presence of a permeative growth pattern may help to distinguish LGCOS from similar benign lesions histologically. In the present case, the open biopsy specimen showed a proliferation of plump spindle cells admixed with branching and anastomosing trabeculae of woven bone. There was neither cytological atypia nor mitotic activity. These features resulted in the initial mis-diagnosis of fibrous dysplasia. In fact, there are several reported cases of LGCOS mimicking fibrous dysplasia, where a limited tissue sample is used (15-17).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Coronal magnetic resonance images of low-grade central osteosarcoma involving the third metatarsal bone. The lesion exhibits intermediate signal intensity on T1-weighted sequence (A) and moderately-high signal intensity on T2-weighted sequence (B). T1-weighted contrast-enhanced fat-suppressed sequence reveals marked enhancement of the lesion (C).

Recent immunohistochemical studies demonstrated that MDM2 and/or CDK4 were expressed in LGCOS, but not in benign fibrous and fibro-osseous lesions (6, 7). The combination of these two markers can therefore serve as a valuable adjunct in the diagnosis of LGCOS. In the present case, we observed that the tumor cells were positive for CDK4, but negative for MDM2. Previous immunohistochemical studies also showed that LGCOS was more commonly positive for CDK4 than MDM2 (6, 11). These observations may be explained by the possibility that CDK4 staining is relatively resistant to de-calcification by acid-based products. On the other hand, Okada et al. (18) showed that proliferative cell activity evaluated by MIB-1 staining was significantly higher in LGCOS than in fibrous dysplasia, offering an advantage in differential diagnosis. Park et al. (19) also reported that the MIB-1 labeling index was lower in LGCOS than in conventional osteosarcoma. These results indicate that the overall mean MIB-1 labeling index is approximately 10% in LGCOS. In contrast, the present case had a high MIB-1 labeling index of 36.7%.

CGH analyses of LGCOS have revealed the gain or amplification of 12q13-q15 involving MDM2, CDK4, and TSPAN31 genes (7, 10). It is interesting to note that the 12q13-q15 amplification is more common in low-grade osteosarcoma than in high-grade osteosarcoma (20, 21). Moreover, the gain of 12q13-q15 sequences has been shown to correlate with the presence of ring chromosomes in parosteal osteosarcoma (22). The amplification of MDM2 and CDK4 can lead to the deregulation of the cell cycle and may therefore play an important role in the progression of LGCOS.

Cytogenetic analysis of LGCOS revealed an inv(6)(p23q15) as the sole anomaly (9). In addition, a previous CGH study showed a gain of 6p21 in 33% of LGCOS (10). We also identified a rearrangement and an amplification involving chromosome 6p by SKY and CGH. These findings suggest that chromosome 6p alterations seem to recur in LGCOS. On the other hand, amplification of 6p12-p21 has frequently been observed in conventional osteosarcoma (23-27) and appears to be an early event in its pathogenesis. Interestingly, the gain and amplification of murine chromosome regions homologous to human chromosome 6p have also been reported in conditional mouse models of osteosarcoma (28). Several genes with oncogenic potential lie within this chromosome region, such as CDC5 cell division cycle 5-like (CDC5L), runt-related transcription factor 2 (RUNX2), Cyclin D3 (CCND3), vascular endothelial growth factor A (VEGFA), and pim-1 oncogene (PIM1). CDC5L is a cell cycle regulator important for the G2/M transition, and its overexpression may promote mitotic entry and shorten the G2 phase (29). Lu et al. (26) suggested that overexpression of CDC5L through genomic amplification is likely to lead to aberrant cell-cycle control and may contribute to the malignant phenotype of osteosarcoma. RUNX2 is a member of the RUNX family of transcription factors and encodes a nuclear protein with a Runt DNA-binding domain. RUNX2 regulates osteoblast lineage determination and expansion, osteoblast maturation, and terminal differentiation via a complex variety of pathways (30). Recently, Sadikovic et al. (31) reported that RUNX2 overexpression was correlated with a poor response to chemotherapy in osteosarcoma. CCND3 is a member of the cyclin-D family and encodes a protein involved in the regulation of the G1/S transition (32). The amplification of CCND3 has been reported in other types of cancer (33-35). VEGFA is a member of the platelet-derived growth factor/VEGF growth factor family and encodes a protein that is often found as a disulfide-linked homodimer. Its amplification and overexpression have been shown to be poor prognostic factors for survival in osteosarcoma (36, 37). PIM1 is a proto-oncogene and encodes a serine/threonine protein kinase that is involved in cell proliferation, survival, differentiation, apoptosis, and tumourigenesis (38). PIM1 overexpression has been found in several cancer types (39). However, the precise roles of these amplifications in the pathogenesis and progression of LGCOS remain to be elucidated.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

The open biopsy specimen shows a proliferation of spindle cells admixed with bracing trabeculae of woven bone lacking osteoblastic rimming. There is no evidence of cytological atypia. Based on these features, we first made a diagnosis of fibrous dysplasia.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Histological and immunohistochemical findings of low-grade central osteosarcoma. The tumor is composed of spindle cells admixed with irregular bony trabeculae and osteoid (A). Mild cellular atypia and mitotic activity are found (B). The tumor cells are focally positive for cyclin-dependent kinase-4 (C). The MIB-1 labeling index is 36.7% (D).

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

A representative G-banded karyotype of low-grade central osteosarcoma, including two marker chromosomes. Arrows indicate the structural chromosomal aberrations.

Figure 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6.

Spectral karyotyping of low-grade central osteosarcoma illustrating the origins of two marker chromosomes (arrows). A classified image is displayed alongside the reverse 4’,6-diamidino-2-phenylindole image.

Figure 7.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 7.

Comparative genomic hybridization profile of low-grade central osteosarcoma showing a high-level amplification of 6p12-p21 and gains of 8q21-q24, 10p15, 12q13-q15, and 16q23-q24. The line in the middle (gray) is the baseline ratio (1.0); the left (red) and right (green) lines indicate ratio values of 0.8 and 1.2, respectively. Bars on the left (red) and right (green) of each frame indicate losses and gains, respectively. The terminology “1 (12)” represents 12 aberrations detected on chromosome 1; the same applies to other chromosomes shown in the profile.

In summary, we have reported a rare case of LGCOS of the metatarsal bone with complex chromosomal rearrangements. Our case highlights the diagnostic difficulty of this tumor with limited tissue samples and the importance of immunohistochemical and molecular cytogenetic analyses in ambiguous cases. Moreover, our results indicate that chromosome 6p alterations may play a critical role in the pathogenesis of LGCOS.

Acknowledgements

This study was supported in part by Fukuoka Cancer Society, Ogata Foundation, and Foundation for the Promotion of Medical Science.

  • Received October 2, 2012.
  • Revision received October 27, 2012.
  • Accepted October 30, 2012.
  • Copyright© 2012 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Fletcher CDM,
    2. Unni KK,
    3. Mertens F
    1. Inwards CY,
    2. Knuutila S
    : Low grade central osteosarcoma. In: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. Fletcher CDM, Unni KK, Mertens F (eds.). Lyon, IARC Press, pp. 275-276, 2002.
  2. ↵
    1. Iemoto Y,
    2. Ushigome S,
    3. Fukunaga M,
    4. Nikaido T,
    5. Asanuma K
    : Case report 679: Central low-grade osteosarcoma with foci of dedifferentiation. Skeletal Radiol 20: 379-382, 1991.
    OpenUrlCrossRefPubMed
    1. Ogose A,
    2. Hotta T,
    3. Emura I,
    4. Imaizumi S,
    5. Takeda M,
    6. Yamamura S
    : Repeated de-differentiation of low-grade intraosseous osteosarcoma. Hum Pathol 31: 615-618, 2000.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Kenan S,
    2. Ginat DT,
    3. Steiner GC
    : De-differentiated high-grade osteosarcoma originating from low-grade central osteosarcoma of the fibula. Skeletal Radiol 36: 347-351, 2007.
    OpenUrlPubMed
  4. ↵
    1. Kurt AM,
    2. Unni KK,
    3. McLeod RA,
    4. Pritchard DJ
    : Low-grade intraosseous osteosarcoma. Cancer 65: 1418-1428, 1990.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Yoshida A,
    2. Ushiku T,
    3. Motoi T,
    4. Shibata T,
    5. Beppu Y,
    6. Fukayama M,
    7. Tsuda H
    : Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. Mod Pathol 23: 1279-1288, 2010.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Dujardin F,
    2. Binh MB,
    3. Bouvier C,
    4. Gomez-Brouchet A,
    5. Larousserie F,
    6. Muret A,
    7. Louis-Brennetot C,
    8. Aurias A,
    9. Coindre JM,
    10. Guillou L,
    11. Pedeutour F,
    12. Duval H,
    13. Collin C,
    14. de Pinieux G
    : MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol 24: 624-637, 2011.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Bridge JA,
    2. Nelson M,
    3. McComb E,
    4. McGuire MH,
    5. Rosenthal H,
    6. Vergara G,
    7. Maale GE,
    8. Spanier S,
    9. Neff JR
    : Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. Cancer Genet Cytogenet 95: 74-87, 1997.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Grubb G,
    2. Hoctor V,
    3. Venter D,
    4. Choong P
    : Inversion (6)(p23q15) as the sole anomaly in a low-grade intraosseous osteosarcoma. Cancer Genet Cytogenet 109: 70-71, 1999.
    OpenUrlPubMed
  9. ↵
    1. Tarkkanen M,
    2. Böhling T,
    3. Gamberi G,
    4. Ragazzini P,
    5. Benassi MS,
    6. Kivioja A,
    7. Kallio P,
    8. Elomaa I,
    9. Picci P,
    10. Knuutila S
    : Comparative genomic hybridization of low-grade central osteosarcoma. Mod Pathol 11: 421-426, 1998.
    OpenUrlPubMed
  10. ↵
    1. Ragazzini P,
    2. Gamberi G,
    3. Benassi MS,
    4. Orlando C,
    5. Sestini R,
    6. Ferrari C,
    7. Molendini L,
    8. Sollazzo MR,
    9. Merli M,
    10. Magagnoli G,
    11. Bertoni F,
    12. Bohling T,
    13. Pazzagli M,
    14. Picci P
    : Analysis of SAS gene and CDK4 and MDM2 proteins in low-grade osteosarcoma. Cancer Detect Prev 23: 129-136, 1999.
    OpenUrlPubMed
  11. ↵
    1. Lee EY,
    2. Seeger LL,
    3. Nelson SD,
    4. Eckardt JJ
    : Primary osteosarcoma of a metatarsal bone. Skeletal Radiol 29: 474-476, 2000.
    OpenUrlPubMed
    1. Andresen KJ,
    2. Sundaram M,
    3. Unni KK,
    4. Sim FH
    : Imaging features of low-grade central osteosarcoma of the long bones and pelvis. Skeletal Radiol 33: 373-379, 2004.
    OpenUrlPubMed
  12. ↵
    1. Bugnone AN,
    2. Temple HT,
    3. Pitcher JD
    : Low-grade central osteosarcoma of the foot and ankle: Radiographic and pathologic features in two patients: Case report and literature review. Foot Ankle Int 26: 494-500, 2005.
    OpenUrlPubMed
  13. ↵
    1. Choong PF,
    2. Pritchard DJ,
    3. Rock MG,
    4. Sim FH,
    5. McLeod RA,
    6. Unni KK
    : Low-grade central osteogenic sarcoma. A long-term followup of 20 patients. Clin Orthop Relat Res 322: 198-206, 1996.
    OpenUrlCrossRefPubMed
    1. Franceschina MJ,
    2. Hankin RC,
    3. Irwin RB
    : Low-grade central osteosarcoma resembling fibrous dysplasia. A report of two cases. Am J Orthop 27: 432-440, 1997.
    OpenUrl
  14. ↵
    1. Muramatsu K,
    2. Hashimoto T,
    3. Seto S,
    4. Gondo T,
    5. Ihara K,
    6. Taguchi T
    : Low-grade central osteosarcoma mimicking fibrous dysplasia: A report of two cases. Arch Orthop Trauma Surg 128: 11-15, 2008.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Okada K,
    2. Nishida J,
    3. Morita T,
    4. Kakizaki H,
    5. Ishikawa A,
    6. Hotta T
    : Low-grade intraosseous osteosarcoma in northern Japan: advantage of AgNOR and MIB-1 staining in differential diagnosis. Hum Pathol 31: 633-639, 2000.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Park HR,
    2. Jung WW,
    3. Bertoni F,
    4. Bacchini P,
    5. Park JH,
    6. Kim YW,
    7. Park YK
    : Molecular analysis of p53, MDM2 and H-RAS genes in low-grade central osteosarcoma. Pathol Res Pract 200: 439-445, 2004.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Wunder JS,
    2. Eppert K,
    3. Burrow SR,
    4. Gokgoz N,
    5. Bell RS,
    6. Andrulis IL
    : Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. Oncogene 18: 783-788, 1999.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Mejia-Guerrero S,
    2. Quejada M,
    3. Gokgoz N,
    4. Gill M,
    5. Parkes RK,
    6. Wunder JS,
    7. Andrulis IL
    : Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma. Genes Chromosomes Cancer 49: 518-525, 2010.
    OpenUrlPubMed
  19. ↵
    1. Szymanska J,
    2. Mandahl N,
    3. Mertens F,
    4. Tarkkanen M,
    5. Karaharju E,
    6. Knuutila S
    : Ring chromosomes in parosteal osteosarcoma contain sequences from 12q13-15: A combined cytogenetic and comparative genomic hybridization study. Genes Chromosomes Cancer 16: 31-34, 1996.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Forus A,
    2. Weghuis DO,
    3. Smeets D,
    4. Fodstad O,
    5. Myklebost O,
    6. Geurts van Kessel A
    : Comparative genomic hybridization analysis of human sarcomas: II. Identification of novel amplicons at 6p and 17p in osteosarcomas. Genes Chromosomes Cancer 14: 15-21, 1995.
    OpenUrlCrossRefPubMed
    1. Lau CC,
    2. Harris CP,
    3. Lu XY,
    4. Perlaky L,
    5. Gogineni S,
    6. Chintagumpala M,
    7. Hicks J,
    8. Johnson ME,
    9. Davino NA,
    10. Huvos AG,
    11. Meyers PA,
    12. Healy JH,
    13. Gorlick R,
    14. Rao PH
    : Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer 39: 11-21, 2004.
    OpenUrlCrossRefPubMed
    1. Man TK,
    2. Lu XY,
    3. Jaeweon K,
    4. Perlaky L,
    5. Harris CP,
    6. Shah S,
    7. Ladanyi M,
    8. Gorlick R,
    9. Lau CC,
    10. Rao PH
    : Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 4: 45, 2004.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Lu XY,
    2. Lu Y,
    3. Zhao YJ,
    4. Jaeweon K,
    5. Kang J,
    6. Xiao-Nan L,
    7. Ge G,
    8. Meyer R,
    9. Perlaky L,
    10. Hicks J,
    11. Chintagumpala M,
    12. Cai WW,
    13. Ladanyi M,
    14. Gorlick R,
    15. Lau CC,
    16. Pati D,
    17. Sheldon M,
    18. Rao PH
    : Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol Cancer Res 6: 937-946, 2008.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Selvarajah S,
    2. Yoshimoto M,
    3. Ludkovski O,
    4. Park PC,
    5. Bayani J,
    6. Thorner P,
    7. Maire G,
    8. Squire JA,
    9. Zielenska M
    : Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH. Cytogenet Genome Res 128: 199-213, 2010.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Walkley CR,
    2. Qudsi R,
    3. Sankaran VG,
    4. Perry JA,
    5. Gostissa M,
    6. Roth SI,
    7. Rodda SJ,
    8. Snay E,
    9. Dunning P,
    10. Fahey FH,
    11. Alt FW,
    12. McMahon AP,
    13. Orkin SH
    : Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev 22: 1662-1676, 2008.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Bernstein HS,
    2. Coughlin SR
    : A mammalian homolog of fission yeast cdc5 regulates G 2 progression and mitotic entry. J Biol Chem 273: 4666-4671, 1998.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Martin JW,
    2. Zielenska M,
    3. Stein GS,
    4. van Wijnen AJ,
    5. Squire JA
    : The role of RUNX2 in osteosarcoma oncogenesis. Sarcoma 2011: 282745, 2011.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Sadikovic B,
    2. Thorner P,
    3. Chilton-Macneill S,
    4. Martin JW,
    5. Cervigne NK,
    6. Squire J,
    7. Zielenska M
    : Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer 10: 202, 2010.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Motokura T,
    2. Keyomarsi K,
    3. Kronenberg HM,
    4. Arnold A
    : Cloning and characterization of human cyclin D3, a cDNA closely related in sequence to the PRAD1/cyclin D1 proto-oncogene. J Biol Chem 267: 20412-20415, 1992.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Büschges R,
    2. Weber RG,
    3. Actor B,
    4. Lichter P,
    5. Collins VP,
    6. Reifenberger G
    : Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Brain Pathol 9: 435-442, 1999.
    OpenUrlCrossRefPubMed
    1. Kasugai Y,
    2. Tagawa H,
    3. Kameoka Y,
    4. Morishima Y,
    5. Nakamura S,
    6. Seto M
    : Identification of CCND3 and BYSL as candidate targets for the 6p21 amplification in diffuse large B-cell lymphoma. Clin Cancer Res 11: 8265-8272, 2005.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Lopez-Beltran A,
    2. Ordóñez JL,
    3. Otero AP,
    4. Blanca A,
    5. Sevillano V,
    6. Sanchez-Carbayo M,
    7. Muñoz E,
    8. Cheng L,
    9. Montironi R,
    10. de Alava E
    : Cyclin D3 gene amplification in bladder carcinoma in situ. Virchows Arch 457: 555-561, 2010.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Yang J,
    2. Yang D,
    3. Sun Y,
    4. Sun B,
    5. Wang G,
    6. Trent JC,
    7. Araujo DM,
    8. Chen K,
    9. Zhang W
    : Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer 117: 4925-4938, 2011.
    OpenUrlPubMed
  31. ↵
    1. Ługowska I,
    2. Woźniak W,
    3. Klepacka T,
    4. Michalak E,
    5. Szamotulska K
    : A prognostic evaluation of vascular endothelial growth factor in children and young adults with osteosarcoma. Pediatr Blood Cancer 57: 63-68, 2011.
    OpenUrlPubMed
  32. ↵
    1. Wang Z,
    2. Bhattacharya N,
    3. Weaver M,
    4. Petersen K,
    5. Meyer M,
    6. Gapter L,
    7. Magnuson NS
    : Pim-1: A serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2: 167-179, 2001.
    OpenUrlPubMed
  33. ↵
    1. Shah N,
    2. Pang B,
    3. Yeoh KG,
    4. Thorn S,
    5. Chen CS,
    6. Lilly MB,
    7. Salto-Tellez M
    : Potential roles for the PIM1 kinase in human cancer-a molecular and therapeutic appraisal. Eur J Cancer 44: 2144-2151, 2008.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 32, Issue 12
December 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Low-grade Central Osteosarcoma of the Metatarsal Bone: A Clinicopathological, Immunohistochemical, Cytogenetic and Molecular Cytogenetic Analysis
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Low-grade Central Osteosarcoma of the Metatarsal Bone: A Clinicopathological, Immunohistochemical, Cytogenetic and Molecular Cytogenetic Analysis
JUN NISHIO, HIROSHI IWASAKI, SATOSHI TAKAGI, HAJIME SEO, MIKIKO AOKI, KAZUKI NABESHIMA, MASATOSHI NAITO
Anticancer Research Dec 2012, 32 (12) 5429-5435;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Low-grade Central Osteosarcoma of the Metatarsal Bone: A Clinicopathological, Immunohistochemical, Cytogenetic and Molecular Cytogenetic Analysis
JUN NISHIO, HIROSHI IWASAKI, SATOSHI TAKAGI, HAJIME SEO, MIKIKO AOKI, KAZUKI NABESHIMA, MASATOSHI NAITO
Anticancer Research Dec 2012, 32 (12) 5429-5435;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Case Report
    • Discussion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Laparotomy After Total Pelvic Exenteration: Current Status and Techniques for Ileal Conduit Preservation
  • Pregabalin for Opioid-resistant Neuropathic Pain in Bone Metastases
  • Life-threatening Pneumonitis Induced by Osimertinib Monotherapy as a First-line Treatment for Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer: A Retrospective Case-series Study
Show more Clinical Studies

Keywords

  • CDK4
  • cytogenetics
  • low-grade central osteosarcoma
  • MDM2
  • metatarsal bone
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire